Azitra, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Azitra, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $19.10K.
- Azitra, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-03-31 was $1.51K.
- Azitra, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $19.10K.
- Azitra, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $1.51K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2024-12-31 | $19.10K 10-K · filed 2026-02-27 | |
| 2024-03-31 | $19.10K 10-Q · filed 2025-11-12 | |
| 2022-12-31 | $1.51K 10-K · filed 2024-03-15 | |
| 2022-03-31 | $1.51K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |